Tarsus Pharmaceuticals (TARS) Receivables - Net (2021 - 2026)

Tarsus Pharmaceuticals' Receivables - Net history runs 6 years deep, the most recent figure standing at $100.3 million for Q1 2026.

• In Q1 2026, Receivables - Net rose 60.74% year-over-year to $100.3 million; the TTM figure through Mar 2026 stood at $100.3 million (up 60.74% YoY), while the FY2025 annual figure was $85.1 million, up 81.9% from the prior year.
• Receivables - Net was $100.3 million for Q1 2026 at Tarsus Pharmaceuticals, up from $85.1 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $100.3 million in Q1 2026 to a low of $17000.0 in Q1 2022.
• Historically, Receivables - Net has averaged $35.9 million across 5 years, with a median of $29.5 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Receivables - Net slumped 99.93% in 2022, then surged 31441.18% in 2023.
• A 5-year view of Receivables - Net shows it stood at $17000.0 in 2022, then jumped by 97670.59% to $16.6 million in 2023, then surged by 181.33% to $46.8 million in 2024, then surged by 81.9% to $85.1 million in 2025, then gained by 17.97% to $100.3 million in 2026.
• The last three Receivables - Net figures came in at $100.3 million (Q1 2026), $85.1 million (Q4 2025), and $72.6 million (Q3 2025), per Business Quant data.